medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20248425; this version posted December 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 Mechanical ventilation affects respiratory microbiome of COVID-19 patients and its

2 interactions with the host

3

Verónica Lloréns-Rico^{1,2}, Ann C. Gregory^{1,2}, Johan Van Weyenbergh³, Sander Jansen⁴,
Tina Van Buyten⁴, Junbin Qian^{5,6}, Marcos Braz³, Soraya Maria Menezes³, Pierre Van
Mol^{5,6,7}, Lore Vanderbeke⁸, Christophe Dooms^{7,9}, Jan Gunst¹⁰, Greet Hermans¹⁰,
Philippe Meersseman¹¹, CONTAGIOUS collaborators, Els Wauters^{7,9}, Johan Neyts⁴,
Diether Lambrechts^{5,6}, Joost Wauters^{11,12}, Jeroen Raes^{1,2,12,13}

9

¹⁰ ¹ Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology,

11 Rega Institute, KU Leuven, Belgium

12 ² Center for Microbiology, VIB, Leuven, Belgium

¹³ Laboratory for Clinical and Evolutionary Virology, Department of Microbiology and

14 Immunology, Rega Institute, KU Leuven, Belgium

⁴ Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology

16 and Transplantation, Rega Institute, KU Leuven, Belgium

17 ⁵ Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven,

18 Belgium

⁶ VIB Center for Cancer Biology, VIB, Leuven, Belgium

20 ⁷ Department of Pneumology, University Hospitals Leuven, Belgium

⁸ Laboratory of Clinical Bacteriology and Mycology, Department of Microbiology,

22 Immunology and Transplantation, KU Leuven, Belgium

⁹ Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of

24 Chronic Diseases and Metabolism, KU Leuven, Belgium

¹⁰ Laboratory of Intensive Care Medicine, Department of Cellular and Molecular

26 Medicine, KU Leuven, Belgium

27 ¹¹ Laboratory for Clinical Infectious and Inflammatory Disorders, Department of

28 Microbiology, Immunology and Transplantation, KU Leuven, Belgium

29 ¹² These authors contributed equally

30 ¹³ Corresponding author: jeroen.raes@kuleuven.vib.be

31

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 **Keywords:** COVID-19, SARS-CoV-2, respiratory microbiome, single-cell RNA-33 sequencing, host-microbiome interactions

- 34
- 35
- 36 Abstract
- 37

38 Understanding the pathology of COVID-19 is a global research priority. Early evidence 39 suggests that the microbiome may be playing a role in disease progression, yet current 40 studies report contradictory results. Here, we examine potential confounders in 41 COVID-19 microbiome studies by analyzing the upper (n=58) and lower (n=35) 42 respiratory tract microbiome in well-phenotyped COVID-19 patients and controls 43 combining microbiome sequencing, viral load determination, and immunoprofiling. We 44 found that time in the intensive care unit and the type of oxygen support explained 45 the most variation within the upper respiratory tract microbiome, dwarfing (non-46 significant) effects from viral load, disease severity, and immune status. Specifically, 47 mechanical ventilation was linked to altered community structure, lower species- and 48 higher strain-level diversity, and significant shifts in oral taxa previously associated 49 with COVID-19. Single-cell transcriptomic analysis of the lower respiratory tract of 50 ventilated COVID-19 patients identified increased oral microbiota compared to 51 controls. These oral microbiota were found physically associated with proinflammatory 52 immune cells, which showed higher levels of inflammatory markers. Overall, our 53 findings suggest confounders are driving contradictory results in current COVID-19 microbiome studies and careful attention needs to be paid to ICU stay and type of 54 55 oxygen support, as bacteria favored in these conditions may contribute to the 56 inflammatory phenotypes observed in severe COVID-19 patients.

57

58 Introduction

59

60 COVID-19, a novel coronavirus disease classified as a pandemic by the World Health 61 Organization, has caused over 40 million reported cases and 1 million deaths 62 worldwide to date. Infection by its causative agent, the novel coronavirus SARS-CoV-2, 63 results in a wide range of clinical manifestations: it is estimated that around 80% of

64 infected individuals are asymptomatic or present only mild respiratory and/or 65 gastrointestinal symptoms, while the remaining 20% develop acute respiratory distress 66 syndrome requiring hospitalization and oxygen support and, of those, 25% of cases 67 necessitate critical care. Despite a concerted global research effort, many questions 68 remain about the full spectrum of the disease severity. Independent studies from 69 different countries, however, agree that age and sex are the major risk factors for disease severity and patient death¹⁻³, as well as type 2 diabetes and obesity ^{4,5}. Other 70 71 risk factors for critical condition and death are viral load of the patient upon hospital 72 admission⁶⁻⁸ and the specific immune response to infection, with manifestation of a 73 "cytokine storm" in critical patients characterized by increased levels of pro-74 inflammatory cytokines and chemokines, sustaining a disproportionate immune 75 response that may ultimately cause organ failure^{9–11}.

76

77 Despite its close interplay with the immune system and its known associations with 78 host health, little is known about the role of the respiratory microbiota in modulating 79 COVID-19 disease severity, or its potential as a prognostic marker¹². Previous studies 80 exploring other pulmonary disorders have shown that lung microbiota may exacerbate their symptoms and contribute to their severity¹³, potentially through direct crosstalk 81 with the immune system and/or due to bacteremia and secondary infections¹⁴. Few 82 83 studies of the respiratory microbiome in COVID-19 have revealed elevated levels of 84 opportunistic pathogenic bacteria^{15–17}. However, reports on bacterial diversity are 85 contradictory. While some studies report a low microbial diversity in COVID-19 patients^{15,18} that rebounds following recovery¹⁶, others show an increased diversity in 86 87 the COVID-19 associated microbiota¹⁷. These conflicting results could be due to 88 differences in sampling location (upper or lower respiratory tract), severity of the 89 patients, disease stage, or other confounders. While these early findings already 90 suggest that the lung microbiome could be exacerbating or mitigating COVID-19 91 progression, exact mechanisms are yet to be elucidated. Therefore, an urgent need 92 exists for studies identifying and tackling confounders in order to discern true signals 93 from noise.

94

95 To identify potential associations between COVID-19 severity and evolution and the 96 upper and lower respiratory tract microbiota, we used nasopharyngeal swabs and 97 bronchoalveolar lavage (BAL) samples, respectively. For the upper respiratory tract, we 98 longitudinally profiled the nasopharyngeal microbiome of 58 COVID-19 patients during 99 intensive care unit (ICU) treatment and after discharge to a classical hospital ward 100 following clinical improvement, in conjunction with viral load determination and 101 nCounter immune profiling. For the lower respiratory tract, we analyzed microbial 102 signals in cross-sectional single-cell RNA-seq data from of bronchoalveolar lavage (BAL) 103 samples of 22 COVID-19 patients and 13 pneumonitis controls with negative COVID-19 104 qRT-PCR, obtained from the same hospital. The integration of these data enabled us to 105 (1) identify potential confounders of COVID-19 microbiome associations, (2) explore 106 how microbial diversity evolves throughout hospitalization, (3) study microbe-host cell 107 interaction and (4) substantiate a link between the respiratory microbiome and SARS-108 CoV-2 viral load as well as COVID-19 disease severity. Altogether, our results directly 109 point to specific interactions between the microbiota and the immune cells, likely 110 driven by clinical ventilation practices, which could potentially influence COVID-19 111 disease progression and resolution.

- 112
- 113 Results

114

115 The upper respiratory microbiota of COVID-19 patients

116

117 We longitudinally profiled the upper respiratory microbiota of 58 patients diagnosed 118 with COVID-19 based on a positive qRT-PCR test or a negative test with high clinical 119 suspicion based on symptomatology and a chest CT-scan showing alveolar damage. All 120 these patients were admitted and treated at UZ Leuven hospital. Patient demographics 121 for this cohort are shown in Table 1.

122

123 In total, 112 nasopharyngeal swabs from these patients were processed (Figure 1a): 124 the V4 region of the 16S rRNA gene amplified on extracted DNA using 515F and 806R 125 primers, and sequenced on an Illumina MiSeq platform (see Methods). From the same 126 swabs, RNA was extracted to determine SARS-CoV-2 viral loads and to estimate

127 immune cell populations of the host using nCounter (Methods). Of the 112 samples 128 processed and sequenced, 101 yielded over 10,000 amplicon reads that could be 129 assigned to bacteria at the genus level (Figure 1b; Methods). The microbiome of the 130 entire cohort was dominated by the gram-positive genera Staphylococcus and 131 *Corynebacterium*, typical from the nasal cavity and nasopharynx¹⁹.

132

133 Bacterial alpha diversity is strongly associated with ICU stay length

134

135 First, we determined genus-level alpha-diversity for the 101 samples with more than 136 10,000 assigned reads, using Shannon Diversity index (see Methods; Supplementary 137 Table 1). We observed that alpha diversity was not significantly correlated to SARS-138 CoV-2 viral load in nasopharyngeal swabs (Figure 1c). In contrast, we found the 139 Shannon index to be significantly affected by the sampling moment (Kruskal-Wallis 140 test, p-value = 0.0076; Figure 1d), with significant differences between swabs procured 141 upon patient admission and later timepoints, suggesting an important effect of disease 142 progression and/or treatment (i.e. due to antibiotics administered throughout ICU 143 stay). We explored these differences further, and observed that Shannon Diversity 144 index correlated negatively with the number of days spent in ICU at the moment of 145 sampling, with longer ICU stays leading to a lower diversity (Supplementary Figure 1a; 146 ρ =-0.55, p-value=4.4·10⁻⁹). Furthermore, the observed decrease in diversity occurred 147 mostly over the first 2 weeks in ICU (Supplementary Figure 1a). Other severity 148 indicators, such as the patient clinical status (i.e. a qualitative metric used to classify 149 patients into different levels of disease severity) or the type of oxygen support 150 required at the moment of sampling, showed no association with the genus-level 151 Shannon index (Supplementary Figure 1b,c). Therefore, the differences in diversity 152 observed across samples were likely driven by the time spent in ICU, and not 153 specifically by disease progression as other severity indicators were unaffected.

154

155 Since time in ICU had a major effect in alpha diversity, we explored whether it might 156 be masking any effects of viral load, as SARS-CoV-2 load was not associated with the 157 length of the ICU stay (Supplementary Figure 1d). When controlling for the time in ICU 158 (see Methods), we observed that viral load was negatively associated with the

159 Shannon diversity index (ρ =-0.26, p-value=0.0089; Supplementary Figure 1e). Other 160 severity indicators such as the clinical status and the type of oxygen support were not 161 correlated to diversity even after controlling for the confounding effect of ICU stay 162 (Kruskal-Wallis test, p-value>0.05).

163

164 Microbiome composition variation is driven by the type of respiratory support

165

166 We next explored potential associations between the upper respiratory genus-level 167 microbiota composition and the extensive metadata collected in the study. In total, 70 168 covariates related to patient anthropometrics, medication and clinical variables 169 measured in the hospital and host cytokine expression measured in the swabs were 170 tested (Supplementary Table 2). Individually, 19 of these covariates showed a 171 significant correlation to microbiota composition (dbRDA, p-value<0.05;FDR<0.05; 172 Figure 2a). These significant covariates were related to disease and measures of its 173 severity, such as the clinical evaluation of the patient, the total length of the ICU stay, 174 the number of days in ICU at the time of sampling, or the type of oxygen support 175 needed by the patient. Surprisingly, the total SARS-CoV-2 viral load detected in the 176 swabs was not significantly associated to microbiome composition variation 177 (Supplementary Table 2).

178

179 Of the 19 significant covariates, only 2 accounted for 48.7% non-redundant variation in 180 this dataset, with the rest holding redundant information. These were the patient ID, 181 included due to the longitudinal sampling of patients, and confirming that intra-182 individual variation over time is smaller than patient inter-individual variation²⁰, and 183 the type of oxygen support received at the time of sampling (Figure 2a,b). Notably, the 184 type of oxygen support discriminated samples based on ventilation type, with non-185 invasive ventilation samples (groups 1, 2 and 3) separating from samples from 186 intubated patients (groups 4 to 7; PERMANOVA test, R²=0.0642, p-value=0.001).

187

188 To determine if oxygen support also impacted the microbiome at finer taxonomic 189 resolution, we revisited alpha-diversity at species- and strain-level. We defined species 190 as 97% identity 16S OTUs and strains per species as the clustered 16S sequences

191 within each OTU. The species and strain-level diversity per sample were calculated as 192 the number of OTUs and as the mean of the number of strains from five randomly 193 sampled OTU species sampled 1,000 times, respectively. Our analyses revealed both 194 species- and strain-level diversity change with ventilation, even with non-invasive 195 ventilation (e.g. BIPAP, CPAP). Across all samples we observed high species- and low 196 strain-level diversity pre-ventilation, which reversed following any form of ventilation 197 (Figure 2c; Wilcoxon test; p-values<0.05, with the exception of type 7), with the 198 exception of ventilation with inhaled nitric oxide. Further, Species- and strain-level 199 diversity showed a strong inverse correlation (Figure 2d; Pearson's correlation, $R^2 = -$ 200 0.92, p-value = 0.0035).

201

202 Therefore, we evaluated which specific taxa were differentially abundant between 203 samples from intubated and non-intubated patients. In total, 30 genera were more 204 abundant in intubated samples, while 2 genera were more abundant in non-invasively 205 ventilated patients (p-value<0.05;FDR<0.05; Figure 2e, Supplementary Figure 2; 206 Supplementary Table 3). Some of these taxa are common oral microbiome 207 commensals or opportunistic pathogens that had been repeatedly reported as more 208 abundant in COVID-19 patients than in healthy controls, such as Prevotella, Veillonella, Fusobacterium, Porphyromonas or Lactobacillus^{15–17}. Here, we reported higher 209 210 abundance of these genera in intubated COVID-19 patients as compared to non-211 mechanically ventilated patients. This points at mechanical ventilation as a potential 212 confounder of previous COVID-19 studies. Additionally, we found other taxa not 213 previously reported in previous COVID-19 microbiome studies, such as Mycoplasma or 214 Megasphaera (Figure 3c, Supplementary Figure 2), but previously associated to risk of 215 ventilator-associated pneumonia²¹.

216

217 By extracting the amplicon sequence variants (ASVs) corresponding to these 218 differentially abundant genera (see Methods), some of these taxa could be narrowed 219 down to the species level, confirming their origin as typically oral bacteria: for 220 instance, Prevotella species included P. oris, P. salivae, P. denticola, P. buccalis and P. 221 oralis. Within the Mycoplasma genus, ASVs were assigned to Mycoplasma salivarium 222 among other species, an oral bacterium which has been previously associated to the

223 incidence of ventilator-associated pneumonia²¹. When controlling for ventilation type, 224 no taxa were found associated to SARS-CoV-2 viral loads. These results show that 225 further research with larger cohorts and controlling for the relevant confounders 226 highlighted here, such as ventilation type or length of stay in ICU, will be needed to 227 study the specific effect of the viral infection.

228

229 Single-cell RNA-seq identifies oral commensals and opportunist pathogens in the 230 lower respiratory tract

231

232 Next, we explored what the functional consequences of (ventilation-driven) lung 233 microbiome disturbances could be. To do so, we screened single-cell RNA-seq data 234 generated on BAL samples of 35 patients²² to identify microbial reads. All patients in 235 this cross-sectional cohort had clinical symptoms of pneumonia, 22 of them being 236 diagnosed with COVID-19. The other 13 patients with non-COVID-19 pneumonia were 237 hereafter referred to as controls (Table 1). Microbiome read screening of these 238 samples revealed an average of 7,295.3 microbial reads per sample (ranging from 0 to 239 74,226 reads, with only a single sample yielding zero microbial reads; Supplementary 240 Figure 3).

241

242 Among the top taxa encountered in these patients, we found some similarities with 243 the data obtained in nasopharyngeal swabs. The top 15 species detected include 244 Mycoplasma salivarium as the dominating taxon in 5 COVID-19 patients in ICU, as well 245 as different Prevotella members. Non-COVID-19 pneumonia patients in ward (i.e. non-246 intubated) harbored different microbes: 2 patients had a microbiome dominated by 247 Porphyromonas gingivalis, while a single patient had a microbiome dominated by the 248 fungus *Pneumocystis jirovecii*, a known pathogen causing pneumonia²³.

249 Supplementary table 4 shows associations between organism abundances and specific 250 patient metadata: disease, hospital stay and ventilation type. Multiple links with 251 COVID-19 diagnosis were identified (Wilcoxon test, (noncorrected) p-value<0.05; see 252 Methods) but due to the low sample number, none was significant after multiple-test 253 correction. Additionally, as hospital stay (ICU or ward), type of oxygen support 254 (invasive or non-invasive ventilation) and disease (COVID-19 or controls) were highly

255 correlated (Chi-squared test, p-value < 0.0001 for all three pairwise correlations), the 256 effect of these three variables could not be disentangled.

257

258 Bacteria in the lower respiratory tract associate to host cells from the innate immune

- 259 system in COVID-19 patients
- 260

261 Next, we took advantage of the single-cell barcoding and questioned whether the 262 microbial cells that we identified were found in association with host cells, or 263 contrarily, had unique barcodes suggesting a free-living state. In total, 29,886 unique 264 barcodes were identified that matched a total of 46,151 microbial UMIs. The 265 distribution of UMIs per barcode was asymmetrical, ranging from 1 to 201 and with 266 88% of the barcodes having a single UMI. Additionally, 26,572 barcodes (89%) were 267 associated to a single microbial species, the rest being associated to 2 species (8.8%) or 268 more (2.2%).

269

270 Out of the total 29,886 microbial barcodes, only 2,108 were also assigned to host cells, 271 suggesting that the bulk of bacteria found in BAL samples exist as free-living organisms 272 or in bacterial biofilms. However, for those associated to host cells, the distribution 273 across disease types was not random. We found that while 2.3% of the non-COVID-19 274 patient cells were associated to bacterial cells, almost the double (4%) could be 275 observed in COVID-19 patients (Figure 3a; Chi-squared test; p-value $< 2.2 \cdot 10^{-16}$). 276 However, because COVID-19 diagnosis is highly correlated with intubation in this 277 cohort, this effect could be due to higher intubation rates in COVID-19 patients. Within 278 COVID-19 patients, we also evaluated the overlap between bacteria-associated host 279 cells and cells with detected SARS-CoV-2 reads (Supplementary Table 5). Out of 1033 280 host cells associated with bacteria in these patients and 343 cells with detected SARS-281 CoV-2 reads, only one cell was positive for both. A binomial test for independence of 282 virus and bacteria detection in the same host cell, showed that the observed co-283 occurrence in one cell only was highly unlikely (p-value=5.7·10⁻⁴), therefore suggesting 284 mutual exclusion of microbiome members and viruses in the same host immune cells.

285

286 We also explored whether host-associated bacterial reads would preferentially be 287 linked with specific cell types, taking into account the varying frequencies of cell types 288 in COVID-19 patients and controls (see Methods). Such a preferential association 289 would suggest that these observations are biologically relevant and not an artifact of 290 the single-cell sample and library preparation. Among control patients, cell types were 291 similarly distributed in both groups (i.e. with and without bacteria), with only a 292 preferential association of microbial cells with neutrophils (p-value = $3.61 \cdot 10^{-12}$; Figure 293 3b; Supplementary Figure 4). However, in COVID-19 patients, three cell types were 294 significantly associated with bacteria: neutrophils (p-value $< 2.2 \cdot 10^{-16}$), monocytes ((p-295 value = $4.82 \cdot 10^{-5}$) and monocyte-derived macrophages (p-value < $2.2 \cdot 10^{-16}$; Figure 3b; 296 Supplementary Figure 4). We also found that different bacteria associate with distinct 297 host cells. For instance, in COVID-19 patients, bacteria from the Mycoplasma genus 298 preferentially associated to monocyte-derived macrophages (p-value = $2.28 \cdot 10^{-7}$), 299 while Rothia (p-value = $8.21 \cdot 10^{-4}$), Enterobacter (p-value = $2.59 \cdot 10^{-5}$), or Klebsiella (p-300 value = $3.12 \cdot 10^{-9}$) are enriched in monocytes (Figure 3c).

301

302 Last, we investigated whether the associations of bacteria to host cells are linked to 303 host cell expression. To do so, we assessed whether expression based cell subtype classification²² for neutrophils, monocytes and macrophages showed non-random 304 305 associations with bacteria across all samples in this cohort. Among the neutrophils, a 306 subtype of inflammatory neutrophils characterized by expression of the calgranulin 307 S100A12 was enriched in bacteria-associated cells (p-value 7.18·10⁻⁶; Figure 3d,e). This 308 subset of cells was also found to be enriched in SARS-CoV-2 nucleocapsid gene reads²², 309 suggesting that the same cell type responsible for defense against the virus would be 310 responding to potentially invasive bacteria in the lung. This subgroup is characterized 311 by the expression of the calprotectin subunits S100A8 and S100A9. It is known that 312 S100A8/A9 heterodimer secretion is increased in infection-induced inflammation and 313 has some antibacterial effects mediated by secretion of pro-inflammatory cytokines, 314 release of reactive oxygen species and recruitment of other inflammatory cells, as well 315 as chelation of Zn²⁺ necessary for bacterial enzymatic activity²⁴. These mechanisms are 316 mediated by binding of the S100A8/A9 dimer to TLR4 receptors to trigger the release 317 of pro-inflammatory cytokines such as IL-6 and TNF- α , and thus may contribute to

sustain or exacerbate inflammation²⁵. Therefore, the association with bacteria could, 318 319 at least in part, explain the inflammatory phenotype of this neutrophil subset. To 320 further examine this hypothesis, we explored differential gene expression between bacteria-associated and non-associated S100A12^{hi} neutrophils (Supplementary Table 321 322 6). Because association of these cells with SARS-CoV-2 and with bacteria was mutually 323 exclusive, we also compared these changes with the ones triggered by the virus in 324 neutrophils²². Within this subset, neutrophils with co-occurring bacteria showed 325 significantly higher expression (Bonferroni-corrected p-value < 0.05) of pro-326 inflammatory genes, including the cytokine IL1B and some of its target genes (PTSG2), 327 the transcription factors FOS and JUN, and several genes involved in degranulation 328 (S100A9, FOLR3, HSPA1A, HSP90AA1, FCGR3B), (Supplementary Table 6). Among 329 these, FOLR3, a gene encoding for a folate receptor, is found in neutrophil secretory 330 granules and has antibacterial functions, by binding folates and thus depriving bacteria 331 of these essential metabolites²⁶. This response differed to that of virus-engulfing 332 neutrophils in that IFN response genes are not distinctively upregulated by bacteria.

333

Regarding myeloid cells, both inflammatory IL1B^{hi} monocytes (p-value = 2.10⁻¹⁶) as well 334 as a mixed group of CCL2-expressing macrophages (p-value = 5.38.10⁻¹⁰) are enriched 335 336 in bacteria-associated cells (Figure 3f). These inflammatory monocytes are believed to 337 have an important role in the cytokine storm occurring in severe COVID-19 patients. In 338 this case, further gene expression patterns were detected, specific for bacteria-339 associated cells: for CCL2^{hi} macrophages, cells with co-occurring bacteria expressed 340 higher levels of MHC genes of type I and II, suggesting a more active role of these cells 341 in antigen presentation (Bonferroni-corrected p-value < 0.05; Figure 3f; Supplementary 342 Table 6). A similar increase was also observed in monocytes, yet not significant 343 (Supplementary Table 6), possibly due to the lower monocyte abundances in this 344 dataset. Additionally, bacteria-associated macrophages express significantly higher 345 levels of the calprotectin subunits S100A8/A9, similarly to neutrophils, as well as pro-346 inflammatory chemokines (such as CCL4, CXCL10 and CXCL1).

347

348 Altogether, our results suggest that the bacteria detected in these cell subsets via 349 scRNA-seq analyses may be contributing to the inflammatory response observed in the 350 host.

- 351

352 Discussion

353

354 Since the beginning of the COVID-19 pandemic, a massive global effort by the scientific 355 community was undertaken to understand physiopathology of SARS-CoV-2 infection 356 and risk factors affecting disease outcome. In this study, we explored the respiratory 357 microbiota as a potential risk factor for disease severity, and we evaluated the upper 358 and lower respiratory tract microbiota in COVID-19 patients throughout their 359 hospitalization. We linked this data to viral load measurements and immunoprofiling 360 results from nCounter and single-cell RNA sequencing data. To assess robustness of 361 previously reported signals, we investigated the effect of potential confounders based 362 on a broad panel of patient metadata variables.

363

We found that in the upper respiratory tract, while SARS-CoV-2 viral load has a weak 364 365 negative association with bacterial biodiversity, a strong effect of severity indicators 366 such as ICU stay was observed, with diversity decreasing throughout the length of the ICU period, a pattern reminiscent of that seen in other pulmonary conditions^{27,28}. 367

368 This effect of ICU and/or ventilation on microbiome alpha diversity could potentially 369 explain why previous studies on the microbiota of COVID-19 patients show conflicting 370 results regarding diversity: some studies reported lower diversity in sputum or throat 371 swab samples of COVID-19 patients^{15,16,18} while others focusing on the lower 372 respiratory microbiome using bronchoalveolar fluid samples, showed higher bacterial 373 diversity in COVID-19 patients than in controls¹⁷. To further complicate matters, it 374 cannot be excluded that sampling site or processing could also be potential 375 confounders in these studies and/or reflect the different pathologies in the different 376 areas of the respiratory tract.

377

378 We further found that between patient microbiome variation (as measured by genus-379 level microbial beta-diversity) was also affected by different severity indicators such as

380 the clinical status of the patient, or more importantly the type of oxygen support 381 received, with intubated patients harboring a different microbiota than non-intubated 382 patients. The impact of oxygen support was also reflected at the species- and strain-383 levels, with intubation causing a significant decrease and increase, respectively, in 384 diversity. We hypothesize that the introduction of forced oxygen may drive the fast 385 extinction of certain microbial species enabling the diversification of existing or newly 386 colonizing species into new strains. Our results suggest that non-invasive ventilation 387 (e.g. BIPAP, CPAP) can have microbial effects indicating that any form of ventilation 388 may be a tipping point for microbial community differences.

389

390 Importantly, several of the taxa reported to change between intubated and non-391 intubated patients were reported to be linked to diagnosis in previous COVID-19 392 microbiome studies^{15–17}. In our study, no taxa were differentially abundant between 393 COVID-19 positive and negative patients after controlling for patient intubation. This 394 result strongly points at the possibility that intubation and mechanical ventilation are 395 confounding previous results. Indeed, one study comparing COVID-19 patients with 396 patients diagnosed of community-acquired pneumonia found no differences in 397 respiratory microbiome composition between both groups of patients, but both groups did differ from healthy controls²⁹. Together, these results indicate that patient 398 399 intubation or even non-invasive ventilation are to be considered as important 400 confounders when studying the upper respiratory microbiome, and we strongly 401 suggest future COVID-19 microbiome studies should foresee and include strategies to 402 account for this covariate. A recent study found a single ASV corresponding to the 403 genus Rothia that was specific for SARS-CoV-2 patients after controlling for ICU-related 404 confounders³⁰.

405

To better understand the potential functional consequences of these procedures and linked microbial shifts, we also profiled the microbiome of the lower respiratory tract using single-cell data obtained from a cross-sectional cohort of patients derived from the same hospital. Our results show that 'standard' single-cell RNA-seq, even though not optimized for microbial detection and profiling, can identify bacteria alone or in association with specific human cells. Unfortunately, the low numbers of microbial

412 reads obtained in this cohort, together with the fact that ICU stay, COVID-19 diagnosis 413 and intubation are highly correlated in this set of patients, only allow for a descriptive 414 analysis of the results. In this cohort, we identified different oral commensals and 415 opportunistic pathogens previously linked to COVID-19 patients in both groups of 416 samples, thus pointing again at a potential ventilation-linked origin. More interestingly, 417 we identified a subset of bacteria associated with host cells, more specifically with 418 neutrophils, monocytes and macrophages. This enrichment shows that these bacteria 419 are likely not random contaminants, from which an even distribution across cell types 420 (i.e. considering cell type abundances) would be expected. The identity of these host 421 cells suggests that bacteria could have been phagocyted by these innate immune 422 system cells, rather than be attached to the host cell surface. To the best of our 423 knowledge, this is the first study linking interacting host cells and lung microbiome via 424 high-throughput single-cell RNA-seq.

425

426 We find that host cells associated with bacteria, most of which are of oral origin, 427 exhibit pro-inflammatory phenotypes as well as higher levels of MHC for antigen 428 presentation. In this single-cell cohort it was observed that critical COVID-19 patients 429 are characterized by an impaired monocyte to macrophage differentiation, resulting in 430 an excess of pro-inflammatory monocytes, as well as by prolonged neutrophil 431 inflammation²². Given that only these cell types are enriched in bacteria, we 432 hypothesize that the respiratory (or ventilation-linked) microbiome may be playing a 433 role in exacerbating COVID-19 progression in the lower respiratory tract. We verified 434 that this response would likely be driven by bacteria and not SARS-CoV-2, which is also 435 detected mostly in these cell types, as there is almost no overlap in detection of both 436 virus and bacteria in the same cells. However, it must be noted that lack of detection 437 does not completely rule out presence of virus and bacteria within these cells. 438 Therefore, further research is required in order to confirm a causative role of the 439 microbiota in this immune impairment characteristic of critical disease, and to reveal 440 the specific mechanisms involved.

441

The presence of oral taxa in the lung microbiota is not unique of disease conditions. It is known that microaspiration, or the aspiration of aerosol droplets originated in the

444 oral cavity, occurs in healthy individuals and can serve as a route for lung colonization 445 of oral commensals³¹. Such an increase of oral bacteria in the lower respiratory tract 446 could be facilitated when critically ill patients -including but not limited to COVID-19-447 get intubated. Indeed, oral bacteria have been linked to ventilator-associated 448 pneumonia^{32,33}. It is yet to be elucidated whether COVID-19 physiopathology favors 449 lung colonization by oral bacteria or if, in contrast, a lung microbiome previously 450 colonized by oral microbes could also contribute to the disease. What is known is that 451 an increase of oral bacteria in the lower respiratory tract can result in an increased 452 inflammatory phenotype, even in healthy subjects³⁴

453

454 **Conclusion**

455

456 Overall, this study provides a systematic analysis of potential confounders in COVID-19 457 microbiome studies. We identified that ICU hospitalization and type of oxygen support 458 had large impacts on the upper respiratory tract microbiome and have the potential to 459 confound clinical microbiome studies. Among the different types of oxygen support we 460 reported the largest shifts in microbial community structure between intubated and 461 non-intubated patients. We found that oral microbiota was strongly enriched in the 462 upper and lower respiratory tracts of intubated COVID-19 patients. Further, in the 463 lower respiratory tract, microbes were strongly associated with specific pro-464 inflammatory immune cells. This information contributes to a collective body of 465 literature on the pathology of COVID-19 and suggests that careful attention be paid to 466 ICU stay and type of oxygen support when evaluating the role of the lung microbiome 467 on COVID-19 disease progression.

- 468
- 469 Methods

470

471 Study design and patient cohorts

472

All experimental protocols and data analyses were approved by the Ethics Commission
from the UZ Leuven Hospital, under the COntAGIouS observational clinical trial (study
number S63381). The study design is compliant with all relevant ethical regulations,

476 including the Declaration of Helsinki and in the GDPR. All participants gave their 477 informed consent to participate in the study.

478

479 A total of 58 patients from the COntAGIouS observational trial were included as our 480 upper respiratory tract cohort. All patients were admitted to the UZ Leuven hospital 481 with a diagnostic of COVID-19. The disease was diagnosed based on a) a positive qRT-482 PCR test, performed on admission or previously on other hospitals, when patients 483 were transferred from other medical facilities; or b) a chest CT-scan showing alveolar 484 damage and clinical symptoms of the disease. All patients included in the study were 485 admitted to ICU for a variable amount of time. Nasopharyngeal swabs were taken from 486 these patients at different timepoints throughout ICU stay and after ICU discharge, 487 during recovery in ward. A total of 74 swabs were processed for upper respiratory 488 microbiome characterization (Figure 1a).

489

490 To extend our findings from the upper respiratory tract, we also profiled the lower respiratory tract microbiota in a different cohort²² of 35 patients belonging to the 491 492 same observational trial and also recruited at UZ Leuven hospital. This cross-sectional 493 cohort is composed by 22 COVID-19 patients and 13 pneumonitis controls with 494 negative qRT-PCR for SARS-CoV-2, with varying disease severity. Previous data from 495 single-cell RNA-sequencing had been collected for this cohort²². We reanalyzed this 496 single-cell dataset to profile the lower respiratory tract microbiota in these patients.

497

498

499 **RNA/DNA extraction and sequencing**

500

501 Nucleic acid extraction from the swab samples was performed with AllPrep 502 DNA/RNA/miRNA Universal kit (QIAGEN, catnr. 80224). Briefly, swabs from the 503 potentially infectious samples were inactivated by adding 600µL RLT-plus lysis buffer. 504 To increase bacterial cell lysis efficiency, glass beads and DX reagent (Pathogen Lysis 505 Tubes, QIAGEN, catnr. 19091) were added to the lysis buffer, and samples were 506 disrupted in a FastPrep-24[™] instrument with the following program: 1-minute beating 507 at 6.5m/sec, 1-minute incubation at 4°C, 1-minute beating at 6.5m/sec, 1-minute

508 incubation at 4°C. After lysis, the remaining extraction steps followed the 509 recommended protocol from the manufacturer. DNA was eluted in 50μ L EB buffer. 510 Amplification of the V4 region of the 16S gene was done with primers 515F and 806R, 511 using single multiplex identifiers and adaptors as previously described³⁵. RNA was 512 eluted in 30µL of nuclease-free water and used for SARS-CoV-2 viral load 513 determination in the swabs as well as to measure inflammatory markers and cytokines 514 and to estimate host cell populations via marker gene expression using nCounter. In 515 brief, raw nCounter data were processed using nSolver 4.0 software (Nanostring), 516 sequentially correcting three factors for each individual sample: technical variation 517 between samples (using spiked positive control RNA), background correction (using 518 spiked negative control RNA) and RNA content variation (using 15 housekeeping 519 genes). We have previously validated nCounter digital transcriptomics for 520 simultaneous quantification of host immune and viral transcripts³⁶, including 521 respiratory viruses in nasopharyngeal aspirates, even with low RNA yield^{37–39}.

522

523 DNA sequencing was performed on an Illumina MiSeq instrument, generating paired-524 end reads of 250 base pairs.

525

For quality control, reads were demultiplexed with LotuS v1.565⁴⁰ and processed 526 527 following the DADA2 microbiome pipeline using the R packages DADA2⁴¹ and 528 phyloseq⁴². Briefly, reads were filtered and trimmed using the parameters truncQ=11, 529 truncLen=c(130,200), and trimLeft=c(30, 30) and then denoised. After removing 530 chimeras, amplicon sequence variants (ASVs) table was constructed and taxonomy was 531 assigned using the Ribosomal Database Project (RDP) classifier implemented in DADA2 532 (RDP trainset 16/release 11.5). The abundance table was then corrected for copy 533 number, rarefied to even sampling depth, and decontaminated. For decontamination, 534 we used the prevalence-based contaminant identification method in the R package 535 decontam⁴³.

536

537 **16S statistical analysis**

538

539 All the analyses were performed using R v3.6.0 and the packages vegan⁴⁴, $phyloseq^{42}$, CoDaSeq⁴⁵, DESeq2⁴⁶, Biostrings⁴⁷, rstatix⁴⁸ and DECIPHER⁴⁹. 540

541

542 To analyze the 16S amplicon data, technical replicates were pooled and counts from 543 technical replicates were added. For all the analyses using genus-level agglomerated 544 data, only samples containing more than 10,000 reads assigned at the genus level 545 were used (101 samples in total). Alpha-diversity was analyzed using Shannon's 546 Diversity Index. Comparison of the alpha diversity values across different groups was 547 performed using Wilcoxon signed-rank tests for 2-group comparisons, and Kruskal-548 Wallis tests for comparisons across multiple groups. In the latter case, pairwise 549 comparisons (when applicable) were performed using Dunn post-hoc tests. To de-550 confound for the effect of the ICU length, we fitted a quadratic model between the 551 days spent at ICU and the Shannon index using the Im function in R. The residuals of 552 this model were used to test the association with the SARS-CoV-2 viral load.

553

554 Beta diversity analyses were performed using distance-based redundancy analyses 555 (RDA), using Euclidean distances on CLR-transformed data. RDA analyses were 556 performed using the capscale function from vegan. Non-redundant contribution to 557 variation was calculated using the ordiR2step function from vegan, using only the 558 variables that were significant individually in the RDA, and a null model without any 559 explanatory variables. For these analyses, taxa with prevalence lower than 10% were 560 excluded. Metadata variables containing dates, as well as non-informative metadata 561 (containing a single non-NA value or unique for only one patient) were also excluded.

562

563 Differential taxa abundance analyses were performed using DESeq2's likelihood ratio tests and controlling for potential confounders when indicated, including them in the 564 565 null model. All statistical tests are two-sided, and when multiple tests were applied to 566 the different features (e.g. the differential taxa abundances across two conditions) p-567 values were corrected for multiple testing using Benjamini-Hochberg's method.

568

569 In order to explore species-level and strain-level diversity, 16S sequences were first 570 clustered into 97% nucleotide diversity operational taxonomic units (OTUs) using the R

571 packages Biostrings and DECIPHER. These OTUs were used to represents the species-572 level. The number of unique 16S sequences clustered within each OTU were used to 573 represent the number of detectable strains per species. To calculate strain-level 574 diversity per sample, the number of strains of 5 detected OTU species were randomly 575 selected and averaged. This was repeated 1,000x and the average of the all 1,000 576 subsamplings was used as the final strain-level diversity value for each sample, as 577 previously described⁵⁰. To account for uneven sampling assessing diversity differences 578 based on different parameters, we randomly selected and averaged the species- and 579 strain-level diversity of 5 samples per parameter. This was repeated 100x and the 580 subsamplings were used to assess the significant differences between species- and 581 strain-level diversity across the parameters. The average was of all 100 subsamplings 582 was used to as the input for a Pearson's correlation between species- and strain-level 583 diversity.

584

585 Identification of microbial reads in BAL scRNA-seq data

586

587 Single-cell data was processed with an in-house pipeline to identify microbial reads. 588 Only read 2, containing the information on the cDNA, was used. Trimmomatic⁵¹ (v0.38) 589 was used to remove trim low quality bases and discard short reads. Additionally, 590 Prinseq++⁵² (v1.2) was used to discard reads with low-complexity stretches. Following 591 quality control, reads from human and potential sequencing artifacts (phage phiX174) 592 were mapped with STAR⁵³ (v2.7.1) and discarded. The remaining reads were mapped 593 against bacterial genomes using a 2-step approach: first, we scanned the reads using 594 mash screen⁵⁴ (v2.0) against a custom database of 11685 microbial reference genomes 595 including bacteria, archaea, fungi and viruses. Genomes likely to be present in the 596 analyzed sample (selected using a threshold of at least two shared hashes from mash 597 screen) were selected and reads were pseudoaligned to this subset of genomes using 598 kallisto⁵⁵ (v0.44.0). To remove potential artifacts, two additional filters were applied: 599 first, if less than 10 different functions were expressed from a given species, the 600 species was discarded. Second, if one function accounted for more than 95% of the 601 mapped reads of a given species, it was also discarded. These filters were aimed at

602 removing potential artifacts caused by contamination or errors in the genome 603 assemblies used in our database.

604

605 Differences in lower respiratory tract microbial taxa between COVID-19 patients and 606 controls, ICU and ward patients, and invasive and non-invasive ventilation types were 607 calculated using Wilcoxon rank-sum tests on centered-log-ratio (CLR)-transformed 608 data. Prior to CLR data transformation, we filtered the data using the CoDaSeq.filter 609 function, to keep samples with more than 1,000 reads and taxa with a relative 610 abundance above 0.1%. Zeros were imputed using the minimum proportional 611 abundance detected for each taxon. This more lenient approach than the one used for 612 16S data was chosen due to the low number of samples available and the reduced 613 number of bacterial reads identified per sample.

614

615 Bacterial reads were assigned their specific barcodes and UMIs as follows: IDs from the 616 mapped microbial reads were retrieved from the kallisto pseudobam output, and used 617 to retrieve their specific barcodes and UMIs using the raw data files from read 1, assigning each barcode and UMI univocally to a microbial species and function. 618

619

620 Direct associations between bacteria and host cells

621

622 Host single-cell transcriptomics data was obtained from the Seurat⁵⁶ object after 623 preprocessing and integrating the samples of the single-cell cohort, as described 624 previously²². From the Seurat object, the metadata was extracted, including the 625 information on patient group (COVID-19 or control) and severity of the disease 626 (moderate or critical) as well as cell type and subtype annotation corresponding to 627 each barcode. Enrichment of bacteria detected in patient groups or cell types was 628 calculated using chi-squared tests, with effect sizes determined via the standardized 629 residuals. Significance was assessed via post-hoc tests using the R package 630 chisq.posthoc.test⁵⁷.

631

632 For cell types showing an enrichment in associated bacteria, a new Seurat object was 633 created by subsetting the specific cell type. Chi-squared tests were also used to

634 determine enrichment of bacteria-associated cell subtypes. Previous annotations of 635 cell subtypes²² were used to generate new clusters manually and identify marker 636 genes for these subtypes, using the function findAllMarkers from Seurat. This function 637 was also used to find differentially expressed genes between bacteria-associated and 638 not-bacteria-associated host cells of each subtype. When using this function, reported 639 adjusted p-values are calculated using Bonferroni correction by default.

640

641 **Figure legends**

642

643 Figure 1. Sample overview and alpha diversity. a) Longitudinal sampling of patients. 644 Each line represents one patient. Yellow lines span the days spent in ward, while blue 645 lines span the days spent in ICU. Red points mark hospital discharge dates. Crosses 646 indicate the timepoints were swab samples were obtained for microbiome analyses. b) 647 Top 15 most abundant genera in this cohort. Samples with > 10,000 reads assigned to 648 microbial taxa at the genus level were stratified according to the sampling moment: 649 upon admission, throughout the ICU stay or at ICU discharge/during treatment in 650 ward. c) Correlation between the SARS-CoV-2 viral load and Shannon diversity index of 651 all samples. The shaded area surrounding the trend line represents the 95% 652 confidence interval. d) Shannon diversity index of all samples, stratified by the 653 sampling moment: admission, throughout ICU stay or at ICU discharge/during 654 treatment in ward. Boxplots span from the first until the third quartile of the data 655 distribution, and the horizontal line indicates the median value of the data. The 656 whiskers extend from the quartiles until the last data point within 1.5 times the 657 interquartile range, with outliers beyond. Individual data points are also represented.

658

659 Figure 2. Upper respiratory microbiome covariates in COVID-19. a) Significant 660 covariates explaining microbiota variation in the upper respiratory tract in this cohort. 661 Individual covariates are listed on the y-axis, their color corresponds to the metadata 662 category they belong to: technical data, disease-related, microbiological tests, 663 comorbidities or host cell populations or gene expression, the latter measured with 664 nCounter (see Methods). Darker colors refer to the individual variance explained by 665 each of these covariates assuming independency, while lighter colors represent the

666 cumulative and non-redundant variance explained by incorporating each variable to a 667 model using a stepwise RDA analysis. The black horizontal line separates those 668 variables that are significant in the non-redundant analysis on top (Patient ID and 669 oxygen support) from the non-significant ones. b) RDA ordination plot showing the 670 first 2 constrained axes. Ordination is constrained by the two significant variables 671 "Patient ID" and "Oxygen support". Samples are depicted as points, whose color 672 indicates the oxygen support type of the patient and whose shape indicates stay at 673 ward or ICU (at the moment of sampling). Axes indicate the variance explained by the 674 first two constrained components of the RDA analysis. c) Species- (left) and strain-level 675 diversity (right) of the samples, stratified by oxygen support type. d) Pearson 676 correlation between average species- and strain- level diversity for each of the oxygen 677 support categories. e) Significant differences among oxygen support types. 678 Differentially abundant taxa between invasive (red) and non-invasive (blue) ventilated 679 sample. Only the top 10 most significant taxa are shown, as determined by their 680 adjusted p-value. Boxplots span from the first until the third quartile of the data 681 distribution, and the horizontal line indicates the median value of the data. The 682 whiskers extend from the quartiles until the last data point within 1.5 times the 683 interquartile range, with outliers beyond. Individual data points are also represented. 684 Gray lines join samples pertaining to the same patient, taken at different time points.

685

686 Figure 3. Host single cells associated to the lower respiratory tract microbiota. a) 687 relative proportion of cells from negative and positive COVID-19 patients with (red 688 color) and without (blue) associated bacteria. The p-value of a chi-squared test using 689 the count data is shown on top of the panel. b) Cell types enriched in bacteria-690 associated cells. Barplots represent the proportion of cell types without ("No") and 691 with ("Yes") bacteria in COVID-19 positive and negative patients. For each patient 692 class, we tested for enrichment of bacteria-associated cells ("Yes") across the different 693 cell types, using the proportions of non-bacteria associated cells ("No") as background. 694 Asterisks mark the cell types with significant enrichment of bacteria. c) Bacterial 695 genera preferentially associating to specific cell types. The heatmaps show the 696 standardized residuals of a chi-squared test including all bacterial genera and the three 697 host cell types enriched in bacteria, for controls (left) and COVID-19 positive patients

698 (right). Taxa with no significant associations with any of the cell types are not shown. 699 Asterisks denote significant positive or negative associations: enrichments are shown 700 in red; depletions are depicted in blue. d) Host cell subtypes associated with bacteria. 701 The heatmap shows the standardized residuals of a chi-squared test including the 702 subtypes of neutrophils, monocytes and monocyte-derived macrophages with 703 associated bacteria, considering cells without bacteria as background. Asterisks denote 704 significant positive or negative associations: enrichments are shown in red; depletions 705 are depicted in blue. e) Marker genes detected for the 5 different subtypes of 706 neutrophils. The heatmap also shows within-group differences between bacteria-707 associated and bacteria-non-associated cells. f) Myeloid cell functional gene set 708 showing the expression of canonical pro-inflammatory, anti-inflammatory and MHC 709 genes for the two subtypes of myeloid cells significantly associated with bacteria 710 (CCL2^{hi}-macrophages and IL1B^{hi}-monocytes). The heatmap also shows within group 711 differences between bacteria-associated and bacteria-non-associated cells. Statistically 712 significant differences after multiple testing correction are marked with squares. For 713 b)-d) asterisks denote significance as follows: * = p-value ≤ 0.05 ; ** = p-value ≤ 0.01 ; *** = p-value \leq 0.001; **** = p-value \leq 0.0001. 714

- 715
- 716

717 **Supplementary Figure Legends**

718

719 Supplementary Figure 1. Alpha diversity in the upper respiratory tract. a) Correlation 720 between number of days spent in ICU at the moment of sampling and Shannon 721 diversity index. For samples taken after discharge to ward, the total number of days 722 spent in ICU was used. Spearman correlation and p-value are indicated in the upper 723 right corner of the panel. The shaded area surrounding the trend line represents the 724 95% confidence interval. b) Shannon diversity of the samples, grouped by patient 725 clinical status at the moment of sampling. The p-value of a Kruskal-Wallis test is shown 726 in the upper right corner of the panel. c) Shannon diversity of the samples, grouped by 727 type of oxygen support supplied to the patient at the moment of sampling. The p-value 728 of a Kruskal-Wallis test is shown in the upper right corner of the panel. d) Correlation 729 between the days spent in ICU at the moment of sampling and SARS-CoV-2 viral load

730 of the sample. For samples taken after discharge to ward, the total number of days 731 spent in ICU was used. The shaded area surrounding the trend line represents the 95% 732 confidence interval. e) Correlation between SARS-CoV-2 viral load and Shannon 733 diversity index, after controlling for the time spent in ICU. The residuals of a quadratic 734 fit between the Shannon diversity and the days in ICU were correlated to the SARS-735 CoV-2 viral loads measured in the samples. Spearman correlation and p-value are 736 indicated in the upper right corner of the panel. The shaded area surrounding the 737 trend line represents the 95% confidence interval. For b) and c), boxplots span from 738 the first until the third quartile of the data distribution, and the horizontal line 739 indicates the median value of the data. The whiskers extend from the quartiles until 740 the last data point within 1.5 times the interquartile range, with outliers beyond. 741 Individual data points are also represented.

742

743 **Supplementary Figure 2.** Differentially abundant taxa between oxygen support types. 744 The 32 taxa whose abundance is significantly different between non-invasive and 745 invasive ventilation are represented. Boxplots span from the first until the third 746 quartile of the data distribution, and the horizontal line indicates the median value of 747 the data. The whiskers extend from the quartiles until the last data point within 1.5 748 times the interquartile range, with outliers beyond. Individual data points are also 749 represented. Gray lines join samples pertaining to the same patient, taken at different 750 time points. An asterisk next to the genera name indicates that the differences 751 between ventilation type are also significant after controlling for patient ID.

752

753 Supplementary Figure 3. Absolute microbial read counts in single-cell RNA-seq data 754 from BAL samples. The top 15 species detected in our analyses are depicted. Samples 755 are grouped by disease type (control for non-COVID-19 pneumonia patients, or COVID-756 19) and hospital stay (ICU or ward).

757

758 Supplementary Figure 4. Associations of specific cell types with bacteria, for COVID-19 759 and control samples. The colors represent the strength of the association as the 760 standardized residuals of a Chi-squared test. Red colors indicate a positive association 761 (i.e. enrichment) of bacteria for each cell type. Blue colors indicate a negative

762 association (i.e. depletion) of bacteria for a given cell type. Asterisks denote 763 significance as follows: * = p-value \leq 0.05; ** = p-value \leq 0.01; *** = p-value \leq 0.001; 764 **** = p-value ≤ 0.0001 .

765

766 Author contributions

767 VLR, ACG, JW, JR designed the study. SJ, TVW, JN, CD, JG, GH, PM collected and 768 processed the BAL samples. PVM and LV collected the clinical data. JW and EW 769 collected the swabs. VLR, ACG and JVW processed the swabs. JVW, MB and SMM 770 determined SARS-CoV-2 viral loads and host gene expression from swabs. DL and JQ 771 generated the single-cell raw data as well as the processed gene-count matrix with 772 annotations of cell types and subtypes. VLR and AGC analyzed the data. VLR, ACG and 773 JR wrote the manuscript. All authors have read and approved the manuscript.

774

775 Acknowledgments

776 This study has been supported by funding from the VIB Grand Challenges Program. VLR 777 is supported by an FWO senior postdoctoral fellowship (12V9421N). ACG is supported 778 by an EMBO postdoctoral fellowship (ALTF 349-2019). The Raes lab is supported by KU

- 779 Leuven, the Rega institute and VIB.
- 780

781 **Conflict of interest declaration**

- 782 The authors declare no competing interests.
- 783

784 **CONTAGIOUS** collaborators

- 785 Yannick Van Herck, Alexander Wilmer, Michael Casaer, Stephen Rex, Nathalie Lorent, 786 Jona Yserbyt, Dries Testelmans, Karin Thevissen.
- 787

788 Data availability

789 Raw amplicon sequencing data that support the findings of this study have been 790 deposited at the European Genome-phenome Archive (EGA), with accession no. XXX.

791

792 References

- 793
- 794 Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients 1.

is made available under a	C-BY-NC-ND 4.0 International	license.

795		with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 ,
796		1054–1062 (2020).
797	2.	Grasselli, G. et al. Risk Factors Associated with Mortality among Patients with
798		COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern. Med. 180,
799		1345–1355 (2020).
800	3.	Mikami, T. et al. Risk Factors for Mortality in Patients with COVID-19 in New
801		York City. J. Gen. Intern. Med. 1–10 (2020). doi:10.1007/s11606-020-05983-z
802	4.	Guo, W. et al. Diabetes is a risk factor for the progression and prognosis of
803		<scp>COVID</scp> -19. Diabetes. Metab. Res. Rev. 36, (2020).
804	5.	Lighter, J. et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for
805		COVID-19 Hospital Admission. Clinical infectious diseases : an official publication
806		of the Infectious Diseases Society of America 71 , 896–897 (2020).
807	6.	Yu, X. et al. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19
808		progression. Crit. care 24 , 170 (2020).
809	7.	Magleby, R. et al. Impact of Severe Acute Respiratory Syndrome Coronavirus 2
810		Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With
811		Coronavirus Disease 2019. Clin. Infect. Dis. (2020). doi:10.1093/cid/ciaa851
812	8.	Westblade, L. F. et al. SARS-CoV-2 Viral Load Predicts Mortality in Patients with
813		and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell (2020).
814		doi:10.1016/j.ccell.2020.09.007
815	9.	Coperchini, F., Chiovato, L., Croce, L., Magri, F. & Rotondi, M. The cytokine
816		storm in COVID-19: An overview of the involvement of the
817		chemokine/chemokine-receptor system. Cytokine and Growth Factor Reviews
818		53 , 25–32 (2020).
819	10.	Henderson, L. A. et al. On the Alert for Cytokine Storm: Immunopathology in
820		COVID-19. Arthritis and Rheumatology 72 , 1059–1063 (2020).
821	11.	Mehta, P. et al. COVID-19: consider cytokine storm syndromes and
822		immunosuppression. The Lancet 395 , 1033–1034 (2020).
823	12.	Khatiwada, S. & Subedi, A. Lung microbiome and coronavirus disease 2019
824		(COVID-19): Possible link and implications. Human Microbiome Journal 17,
825		100073 (2020).
826	13.	Dickson, R. P., Martinez, F. J. & Huffnagle, G. B. The role of the microbiome in
827		exacerbations of chronic lung diseases. <i>The Lancet</i> 384 , 691–702 (2014).
828	14.	Huffnagle, G. B., Dickson, R. P. & Lukacs, N. W. The respiratory tract microbiome
829		and lung inflammation: A two-way street. <i>Mucosal Immunology</i> 10 , 299–306
830		(2017).
831	15.	Zhang, H. <i>et al.</i> Metatranscriptomic Characterization of COVID-19 Identified A
832		Host Transcriptional Classifier Associated With Immune Signaling. Clin. Infect.
833		<i>Dis.</i> (2020). doi:10.1093/cid/ciaa663
834	16.	Xu, R. et al. Temporal dynamics of human respiratory and gut microbiomes
835		during the course of COVID. <i>medRxiv</i> 2020.07.21.20158758 (2020).
836		doi:10.1101/2020.07.21.20158758
837	17.	Han, Y., Jia, Z., Shi, J., Wang, W. & He, K. The active lung microbiota landscape of
838		COVID-19 patients. <i>medRxiv</i> 2020.08.20.20144014 (2020).
839		doi:10.1101/2020.08.20.20144014
840	18.	Mostafa, H. H. <i>et al.</i> Metagenomic Next-Generation Sequencing of
841		Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19
		, , , , , , , , , , , , , , , , , , ,

842		Patients Downloaded from. <i>MBio</i> 11 , (2020).
843	19.	Ho Man, W., de Steenhuijsen Piters, W. A. & Bogaert, D. The microbiota of the
844		respiratory tract: gatekeeper to respiratory health. (2017).
845		doi:10.1038/nrmicro.2017.14
846	20.	Whelan, F. J. <i>et al.</i> Longitudinal sampling of the lung microbiota in individuals
847		with cystic fibrosis. PLoS One 12, (2017).
848	21.	Nolan, T. J. <i>et al.</i> Low-pathogenicity Mycoplasma spp. alter human monocyte
849		and macrophage function and are highly prevalent among patients with
850		ventilator-acquired pneumonia. <i>Thorax</i> 71 , 594–600 (2016).
851	22.	Wauters, E. et al. Discriminating Mild from Critical COVID-19 by Innate and
852		Adaptive Immune Single-cell Profiling of Bronchoalveolar Lavages. Patrick
853		Matthys 9 , 14 (2020).
854	23.	Harris, J. R., Balajee, S. A. & Park, B. J. Pneumocystis jirovecii pneumonia:
855		Current knowledge and outstanding public health issues. Current Fungal
856		Infection Reports 4 , 229–237 (2010).
857	24.	Wang, S. et al. S100A8/A9 in inflammation. Frontiers in Immunology 9, 1298
858		(2018).
859	25.	Coveney, A. P. <i>et al.</i> Myeloid-related protein 8 induces self-tolerance and cross-
860		tolerance to bacterial infection via TLR4- and TLR2-mediated signal pathways.
861		Nat. Publ. Gr. (2015). doi:10.1038/srep13694
862	26.	Holm, J. & Hansen, S. I. Characterization of soluble folate receptors (folate
863		binding proteins) in humans. Biological roles and clinical potentials in infection
864		and malignancy. Biochimica et Biophysica Acta - Proteins and Proteomics 1868,
865		140466 (2020).
866	27.	Zakharkina, T. <i>et al.</i> The dynamics of the pulmonary microbiome during
867		mechanical ventilation in the intensive care unit and the association with
868		occurrence of pneumonia. doi:10.1136/thoraxjnl-2016-209158
869	28.	Schmitt, F. C. F. et al. Pulmonary microbiome patterns correlate with the course
870		of disease in patients with sepsis-induced ARDS following major abdominal
871		surgery. (2020). doi:10.1016/j.jhin.2020.04.028
872	29.	Shen, Z. et al. Genomic Diversity of Severe Acute Respiratory Syndrome-
873		Coronavirus 2 in Patients With Coronavirus Disease 2019. Clinical infectious
874		diseases : an official publication of the Infectious Diseases Society of America 71 ,
875		713–720 (2020).
876	30.	Marotz, C. et al. Title: Microbial context predicts SARS-CoV-2 prevalence in
877		patients and the hospital built environment. medRxiv 2020.11.19.20234229
878		(2020). doi:10.1101/2020.11.19.20234229
879	31.	Bassis, C. M. et al. Analysis of the upper respiratory tract microbiotas as the
880		source of the lung and gastric microbiotas in healthy individuals. <i>MBio</i> 6, (2015).
881	32.	Brennan, M. T. et al. The role of oral microbial colonization in ventilator-
882		associated pneumonia. Oral Surgery, Oral Med. Oral Pathol. Oral Radiol.
883		Endodontology 98 , 665–672 (2004).
884	33.	Stonecypher, K. Ventilator-Associated Pneumonia: The Importance of Oral Care
885		in Intubated Adults. Crit. Care Nurs. Q. 33, 339–347 (2010).
886	34.	Segal, L. N. et al. Enrichment of the lung microbiome with oral taxa is associated
887		with lung inflammation of a Th17 phenotype. <i>Nat. Microbiol.</i> 1 , 1–11 (2016).
888	35.	Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D.

889		Development of a dual-index sequencing strategy and curation pipeline for
890		analyzing amplicon sequence data on the miseq illumina sequencing platform.
891		Appl. Environ. Microbiol. 79 , 5112–5120 (2013).
892	36.	Moens, B. <i>et al.</i> Simultaneous RNA quantification of human and retroviral
	50.	•
893		genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines.
894		Virol. J. 9 , 171 (2012).
895	37.	Fukutani, K. F. et al. Pathogen transcriptional profile in nasopharyngeal aspirates
896		of children with acute respiratory tract infection. J. Clin. Virol. 69, 190–196
897		(2015).
898	38.	Bouzas, M. L. <i>et al.</i> Diagnostic accuracy of digital RNA quantification versus real-
899	50.	time PCR for the detection of respiratory syncytial virus in nasopharyngeal
900		aspirates from children with acute respiratory infection. J. Clin. Virol. 106 , 34–40
901		(2018).
902	39.	Fukutani, K. F. et al. In situ immune signatures and microbial load at the
903		nasopharyngeal interface in children with acute respiratory infection. Front.
904		Microbiol. 9 , (2018).
905	40.	Hildebrand, F., Tadeo, R., Voigt, A. Y., Bork, P. & Raes, J. LotuS: An efficient and
906		user-friendly OTU processing pipeline. <i>Microbiome</i> 2 , 30 (2014).
907	41.	Callahan, B. J. <i>et al.</i> DADA2: High-resolution sample inference from Illumina
	41.	
908		amplicon data. <i>Nat. Methods</i> 13 , 581–583 (2016).
909	42.	McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible
910		Interactive Analysis and Graphics of Microbiome Census Data. PLoS One 8,
911		e61217 (2013).
912	43.	Davis, N. M., Proctor, Di. M., Holmes, S. P., Relman, D. A. & Callahan, B. J. Simple
913		statistical identification and removal of contaminant sequences in marker-gene
914		and metagenomics data. <i>Microbiome</i> 6 , 226 (2018).
915	44.	Oksanen, J. <i>et al.</i> vegan: Community Ecology Package. (2019).
916	45.	Gloor, G. B., Wu, J. R., Pawlowsky-Glahn, V. & Egozcue, J. J. It's all relative:
917		analyzing microbiome data as compositions. Ann. Epidemiol. 26, 322–329
918		(2016).
919	46.	Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
920		dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
921	47.	Pagès, H., Aboyoun, P., Gentleman, R. & DebRoy, S. Biostrings: Efficient
922		manipulation of biological strings. (2019).
923	48.	Kassambara, A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests.
924	40.	(2020).
	40	
925	49.	Wright, E. S. Using DECIPHER v2.0 to Analyze Big Biological Sequence Data in R.
926	50.	Gregory, A. C. et al. Marine DNA Viral Macro- and Microdiversity from Pole to
927		Pole. <i>Cell</i> 177 , 1109-1123.e14 (2019).
928	51.	Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for
929		Illumina sequence data. <i>Bioinformatics</i> 30 , 2114–2120 (2014).
930	52.	Cantu, V. A., Sadural, J. & Edwards, R. PRINSEQ++, a multi-threaded tool for fast
931		1 and efficient quality control and 2 preprocessing of sequencing datasets.
932		(2019). doi:10.7287/peerj.preprints.27553v1
	ГЭ	
933	53.	Dobin, A. <i>et al.</i> STAR: Ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> 29 , 15–
934		21 (2013).
935	54.	Ondov, B. D. <i>et al.</i> Mash Screen: high-throughput sequence containment

936	actimation for gonomo discou	ery. Genome Biol. 20 , 232 (2019).
9.30	esumation for genome discover	EIV. GENOME BIOI. ZU . 232 (2019).

- Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic 937 55. 938 RNA-seq quantification. Nat. Biotechnol. 34, 525-527 (2016).
- 939 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell 56. 940 transcriptomic data across different conditions, technologies, and species. Nat. 941 Biotechnol. 36, 411-420 (2018).
- 942 57. Ebbert, D. chisq.posthoc.test: A Post Hoc Analysis for Pearson's Chi-Squared 943 Test for Count Data. (2019).

944

Figure 1







Figure 2


It is made available under a CC-BY-NC-ND 4.0 International license .



Norm. counts (log2) 30 20 10








7.5

5.0







Figure 3



	Upper respiratory tract (swabs)	Lower respiratory tract (BAL)
Number of patients	58	35
COVID-19 positive (%)	58 (100%)	22 (62.9%)
Age (range)	61.2 (37-83)	64.1 (45-85)
Female sex (%)	13 (22.4%)	12 (34.3%)
BMI (range)	28.9 (22-46.7)	26.2 (16-36.4)
Diabetic (%)	12 (20.7%)	6 (17.1%)
Days in ICU (range)	21.4 (2-72)	NA
Days in hospital (range)	32.5 (6-86)	NA

Table 1. Patient demographics of our upper and lower respiratory tract cohorts